Results 11 to 20 of about 400,118 (290)

Acute Myeloid Leukemia

Apollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +3 more sources

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

Haematologica, 2008
We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany.
Brunangelo Falini, Maria Paola Martelli, Cristina Mecucci, Arcangelo Liso, Niccolò Bolli, Barbara Bigerna, Alessandra Pucciarini, Stefano Pileri, Giovanna Meloni, Massimo F. Martelli, Torsten Haferlach, Susanne Schnittger   +11 more
doaj   +1 more source

The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA [PDF]

, 2016
Alterations in genetic programs required for terminal myeloid differentiation and aberrant proliferation characterize acute myeloid leukemia (AML) cells.
Bozzoni, Irene, Fatica, Alessandro, Fazi, Francesco, Iosue', Ilaria, Larivera, Simone, Legnini, Ivano, Mangiavacchi, Arianna, Masciarelli, Silvia, Sorci, Melissa   +8 more
core   +2 more sources

Uncommon CD markers in acute myeloid leukemia

Bangabandhu Sheikh Mujib Medical University Journal, 2018
This study was done to assess the unusual CD expression in 100 cases of acute myeloid leukemia from October 2016 to April 2018. The age limit was from 3 to 50 years.
Azad Abul Kalam, Md. Rafiquzzaman Khan, A. B. M. Hassan Habib, Masuda Begum   +3 more
doaj   +1 more source

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach   +5 more
doaj   +1 more source

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI, Greco M, LA NASA, GIORGIO   +2 more
core   +2 more sources

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

Haematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini, Cristina Mecucci, Giuseppe Saglio, Francesco Lo Coco, Daniela Diverio, Patrick Brown, Fabrizio Pane, Marco Mancini, Maria Paola Martelli, Stefano Pileri, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger   +12 more
doaj   +1 more source